NEWYou can now listen to Fox News articles!
FIRST ON FOX: Dr. Heidi Overton, a former nominee for Food and Drug Administration (FDA) commissioner, had committed to establishing a binding timeline and clear parameters for a safety study on the abortion medication mifepristone, the office of Sen. Josh Hawley, R-Mo., told Fox News Digital Friday.
Hawley, a member of the Senate Health, Education, Labor and Pensions (HELP) Committee, has spent months pressing federal health officials for accountability over the delayed assessment.
“These are major pro-life wins that help ensure a robust study and the potential reinstatement of critical safeguards on the abortion drug that President Biden stripped away,” Hawley said in a statement to Fox News Digital.
“I will expect that the FDA will live up to these promises, and as a member of the HELP Committee, any future FDA commissioner nominee must commit to carrying this through in order to earn my support.”
TRUMP TO NOMINATE DR HEIDI OVERTON AS NEXT FDA COMMISSIONER
The White House pulled Heidi Overton’s nomination one day before a Senate committee vote. President Donald Trump hailed Overton as a “ROCKSTAR” in August when he picked the physician and White House advisor to succeed Marty Makary, who resigned in May.
According to Hawley’s office, the Trump administration had pledged to finalize a comprehensive mifepristone safety study by March 2027, with the FDA committing to enact regulatory changes supported by the findings no later than September 2027.
Updated safety protocols would have applied to both brand-name mifepristone and its generic equivalents.
FEDERAL APPEALS COURT BLOCKS MAILING OF ABORTION PILLS IN RULING WITH NATIONWIDE EFFECT

Hawley’s office noted that the potential study will analyze Medicaid and commercially available data spanning periods before and after the Biden administration lifted restrictions.
Federal oversight of the medication has drawn sustained scrutiny since 2023, when the Biden administration eliminated requirements mandating in-person doctor visits and in-person dispensing.
HAWLEY URGES DOJ PROBE INTO ABORTION PILL MAKER OVER SAFETY CONCERNS
The FDA’s review has faced repeated postponements despite earlier pledges by officials to release a study in 2025 amid concerns from critics that the agency was excluding critical data.
“FDA has explained its intention to quickly complete its ongoing review using appropriate data and qualified experts, follow the evidence, and make the scientific basis and results public to the greatest extent permitted by law,” Overton wrote in her Senate committee confirmation questionnaire prior to her nomination being pulled.
WHITE HOUSE PULLS TRUMP’S FDA PICK HEIDI OVERTON ON EVE OF SENATE PANEL VOTE

CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“If confirmed, I would support completing that work as expeditiously as practicable while preserving the integrity of the scientific review,” she added.
In March, Hawley urged fellow Republicans to back his legislation to ban mifepristone.
“The evidence is now clear,” he said at the time. “Mifepristone is almost always fatal to the unborn child, but it is also significantly dangerous for women. The drug companies that make this drug know this but continue to profit from the drug’s nearly unregulated distribution, largely insulated from liability. Congress can no longer ignore these dangers.”
Read the full article here














